New hope: drug combo aims to stop brain tumors in breast cancer patients
NCT ID NCT05323955
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug tucatinib to standard therapy (trastuzumab/pertuzumab or T-DM1) can prevent new or worsening brain metastases in people with advanced HER2+ breast cancer. About 48 participants who have stable disease elsewhere but a new brain tumor will receive the combination after local treatment like radiation. The goal is to see if this approach extends the time before brain tumors progress.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tucatinib (Tukysa) added to trastuzumab (Herceptin), pertuzumab (Perjeta), or T-DM1
What this could lead to
If it works, this could offer a new way to delay or prevent new brain metastases in patients with advanced HER2+ breast cancer.
What could go wrong
This is a small Phase 2 trial with only 48 participants, so results may not apply to everyone. Adding tucatinib may cause side effects like diarrhea or liver problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
University of California San Francisco
San Francisco, California, 94158, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
Washington University in St. Louis
St Louis, Missouri, 63130, United States